Researchers have discovered an unexpected mechanism driving the spread of Alzheimer's disease through the brain: a common protein called Arc, which normally helps neurons communicate, also serves as a carrier that transports toxic Tau proteins from diseased cells to healthy ones. The findings, published in the journal Cell, point to a potential new strategy for slowing the relentless progression of Alzheimer's.
How Arc Helps Toxic Tau Travel
Alzheimer's disease is characterized by the buildup of toxic Tau proteins that form sticky tangles inside neurons, interfering with the cell's internal transport system and eventually killing the cell. As Tau spreads to new areas of the brain, the disease progresses, leading to worsening memory loss and cognitive decline.
In a study led by Jason Shepherd, PhD, at University of Utah Health, researchers compared mouse models of Alzheimer's with and without the Arc protein. Their experiments showed that Arc is essential for moving toxic Tau between neurons.
Under normal conditions, Arc packages itself inside tiny membrane-bound sacs called extracellular vesicles (EVs), which travel from one neuron to another carrying important cellular signals. The researchers found that toxic Tau exploits this natural communication system, hitching a ride inside these microscopic vesicles to travel from an unhealthy neuron into a healthy one.
"I'm excited by the fact that we've identified a new way of potentially stopping the progression of Alzheimer's disease," Shepherd said.
Tau Turns Healthy Brain Cells Toxic
Every neuron contains Tau, but in Alzheimer's the protein begins clumping into large tangles that Mitali Tyagi, PhD, the study's first author, describes as "glue monsters."
"They glue together and block transportation within the neuron," Tyagi explained. "But they can break down into smaller glue monsters, called Tau seeds, which can then get transferred to a new neuron. And once this Tau seed comes into contact with healthy Tau, it is able to corrupt it."
In Alzheimer's mouse models, the team found extracellular vesicles containing both Arc and sticky Tau in brain tissue. These vesicles could enter healthy cells and trigger the formation of new Tau tangles. When Arc was removed, the transfer of Tau was "severely, severely reduced — it was almost gone," Tyagi said.
A Double-Edged Sword
The discovery comes with an important complication: Arc also performs a protective role in early disease stages. By helping neurons expel excess toxic Tau, Arc allows damaged cells to survive longer. In mice without Arc, toxic Tau remained trapped inside neurons, causing those already sick cells to die more quickly.
This suggests that blocking Tau release entirely might backfire. Instead, the most promising therapeutic strategy may be to intercept Tau-containing extracellular vesicles after they leave diseased neurons but before they reach healthy ones — stopping the spread without accelerating the death of already-affected cells.
From Mice to Humans
The researchers also found extracellular vesicles containing both Arc and Tau in human brain tissue, suggesting the same mechanism exists in people. However, Shepherd cautioned that much more research is needed before any potential therapy reaches patients.
"Most of the work we've been doing is in mice, not in humans," he said. "We have some clues that whatever is happening in these mice could also be happening in humans, but we don't know that yet. And we're far away from saying that we're developing a treatment for anything. But it could open new avenues."
The study, titled "Arc mediates intercellular tau transmission via extracellular vesicles," was funded by the National Institutes of Health, the Chan-Zuckerberg Initiative, the Alzheimer's Association, and other organizations.
What This Means
Alzheimer's disease affects more than 55 million people worldwide, with numbers expected to triple by 2050. Current treatments can manage symptoms but cannot stop or reverse the disease. If further research confirms the Arc-Tau mechanism in humans, it could lead to a new class of therapies designed not to eliminate Tau altogether, but to contain its spread — a strategy more akin to quarantine than eradication.
For patients with early-stage Alzheimer's or mild cognitive impairment, such an approach could potentially slow or halt further damage, preserving cognitive function for years longer than currently possible.
